Prostate Cancer

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening. Read More

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity. Read More

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer. Read More

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets. Read More

An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk. Read More

Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease. Read More

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk. Read More

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer. Read More

“When it’s you, it’s a whole different feeling,” Orrin Ingram said, gazing at logs burning in the fireplace. Read More

A federal task force has changed its recommendation about prostate cancer screening for some older men. The United States Preventive Services Task Force (USPSTF) now recommends that men between the ages of 55 to 69 consult with their physicians about getting routine screening blood tests to detect prostate cancer. Read More

Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA). Read More

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Read More

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression. Read More

Beginning this week, Vanderbilt men will have a good excuse to ignore their razors and let their facial hair grow. November has been dubbed “Movember,” a time when men are encouraged to grow a moustache to raise funds and awareness for prostate cancer. Read More

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men. Read More

Austin Kirschner, M.D., Ph.D., assistant professor of Radiation Oncology and Cancer Biology, has received the Urology Care Foundation Research Scholars Award for the study of advanced prostate cancer. Read More

Vanderbilt-Ingram Cancer Center (VICC) patient William Ostman smiled while gazing into a camera lens and declared, “I am a prostate cancer survivor.” Read More

Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream. Read More

A combination of two types of therapy may be more effective in treating castration-resistant prostate cancer. Read More

One of the most formidable weapons in a cancer’s arsenal is the ability to spread to other organs. Read More